A novel approach to accurately measuring the burden of hospitalisations for cardiovascular disease in people with diabetes: A pilot study.

diabetes mellitus heart failure hospital admission myocardial infarction stroke

Journal

Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858

Informations de publication

Date de publication:
27 Jan 2024
Historique:
revised: 09 01 2024
received: 09 10 2023
accepted: 17 01 2024
medline: 27 1 2024
pubmed: 27 1 2024
entrez: 27 1 2024
Statut: aheadofprint

Résumé

To determine the reliability of hospital discharge codes for heart failure (HF), acute myocardial infarction (AMI) and stroke compared with adjudicated diagnosis, and to pilot a scalable approach to adjudicate records on a population-based sample. A population-based sample of 685 people with diabetes admitted (1274 admissions) to one of three Australian hospitals during 2018-2020 were randomly selected for this study. All medical records were reviewed and adjudicated. Cardiovascular diseases were the most common primary reason for hospitalisation in people with diabetes, accounting for ~17% (215/1274) of all hospitalisations, with HF as the leading cause. ICD-10 codes substantially underestimated HF prevalence and had the lowest agreement with the adjudicated diagnosis of HF (Kappa = 0.81), compared with AMI and stroke (Kappa ≥ 0.91). While ICD-10 codes provided suboptimal sensitivity (72%) for HF, the performance was better for AMI (sensitivity 84%; specificity 100%) and stroke (sensitivity 85%; specificity 100%). A novel approach to screen possible HF cases only required adjudicating 8% (105/1274) of records, correctly identified 78/81 of HF admissions and yielded 96% sensitivity and 98% specificity. While ICD-10 codes appear reliable for AMI or stroke, a more complex diagnosis such as HF benefits from a two-stage process to screen for suspected HF cases that need adjudicating. The next step is to validate this novel approach on large multi-centre studies in diabetes.

Identifiants

pubmed: 38279705
doi: 10.1111/dme.15291
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e15291

Subventions

Organisme : AstraZeneca Australia

Informations de copyright

© 2024 Diabetes UK.

Références

Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757-767. doi:10.1016/s0140-6736(22)01429-5
Birkeland KI, Bodegard J, Eriksson JW, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study. Diabetes Obes Metab. 2020;22:1607-1618. doi:10.1111/dom.14074
Quach S, Blais C, Quan H. Administrative data have high variation in validity for recording heart failure. Can J Cardiol. 2010;26:306-312. doi:10.1016/s0828-282x(10)70438-4
Rodrigues C, Odutayo A, Patel S, et al. Accuracy of cardiovascular trial outcome ascertainment and treatment effect estimates from routine health data: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2021;14:e007903.
Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol. 1995;5:278-285. doi:10.1016/1047-2797(1094)00093-00099
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121-130. doi:10.1016/S0140-6736(1019)31149-31143
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72:2231-2264. doi:10.1016/j.jacc.2018.2208.1038
Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:1158-1192. doi:10.1161/STR.1150b1013e31820a38364
Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457-507. doi:10.1159/000131083
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22:276-282.
Tomic D, Salim A, Morton JI, Magliano DJ, Shaw JE. Reasons for hospitalisation in Australians with type 2 diabetes compared to the general population, 2010-2017. Diabetes Res Clin Pract. 2022;194:110143. doi:10.1016/j.diabres.2022.110143
Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2015;3:105-113. doi:10.1016/s2213-8587(14)70219-0
Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140:e294-e324. doi:10.1161/cir.0000000000000691
Morton JI, Lazzarini PA, Shaw JE, Magliano DJ. Trends in the incidence of hospitalization for major diabetes-related complications in people with type 1 and type 2 diabetes in Australia, 2010-2019. Diabetes Care. 2022;45:789-797. doi:10.2337/dc21-2268
McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis. PLoS One. 2014;9:e104519. doi:10.1371/journal.pone.0104519
Ingelsson E, Arnlöv J, Sundström J, Lind L. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail. 2005;7:787-791. doi:10.1016/j.ejheart.2004.12.007
Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, heart failure Association of the European Society of cardiology, Japanese heart failure society and writing Committee of the Universal Definition of heart failure: endorsed by the Canadian heart failure society, heart failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese heart failure association. Eur J Heart Fail. 2021;23:352-380. doi:10.1002/ejhf.2115

Auteurs

Quan Huynh (Q)

Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

John Burgess (J)

Royal Hobart Hospital, Hobart, Tasmania, Australia.
School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.

Kate Flentje (K)

Royal Hobart Hospital, Hobart, Tasmania, Australia.

Neville Tan (N)

Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Western Health, Melbourne, Victoria, Australia.

Riley Batchelor (R)

Alfred Hospital, Melbourne, Victoria, Australia.

Thomas H Marwick (TH)

Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Royal Hobart Hospital, Hobart, Tasmania, Australia.

Jonathan E Shaw (JE)

Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

Classifications MeSH